Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
About Chromadex Corp
Chromadex Corp (CDXC) is a globally recognized integrated nutraceutical and bioscience company committed to improving the quality of life through advanced research on healthy aging. The company is deeply invested in understanding the mechanisms by which cellular processes, particularly those involving nicotinamide adenine dinucleotide (NAD+), impact the aging process. With a core focus on innovative science, Chromadex has developed a multifaceted business model that spans from research breakthroughs to commercially available consumer products, ensuring that its scientific discoveries translate into meaningful daily benefits.
Business Model and Core Segments
Chromadex’s operational framework is built on three primary segments that work in unison to deliver high-quality, science-based nutraceutical innovations:
- Consumer Products: This segment is primarily responsible for marketing and distributing products directly to the consumer market. Its portfolio features formulations designed to support healthy aging by leveraging proprietary, scientifically validated ingredients. The company’s flagship product, built around the NAD+ precursor nicotinamide riboside (NR), exemplifies its commitment to translating rigorous research into everyday solutions.
- Ingredients Segment: Focused on the development and licensing of novel ingredients, this segment utilizes high-caliber scientific research to create bioactive compounds. These innovations are targeted for use in various applications, ranging from dietary supplements to functional foods, ensuring that the expertise of Chromadex is shared widely across the industry.
- Analytical Reference Standards and Services: This area underpins the rigorous quality control and analytical validation processes that are crucial to research and product development. By offering specialized standards and services, Chromadex supports both internal development and external quality assurance needs in a scientifically robust manner.
Research and Innovation
At the heart of Chromadex’s operations is a steadfast commitment to research and development. The company partners with leading universities and research institutions worldwide to explore the potential of critical biochemical pathways related to aging. This collaborative approach not only strengthens its research capabilities but also ensures that the ingredients developed are based on solid scientific evidence. The integration of cutting-edge bioscience and precise analytical methodologies solidifies its position as a trusted name in the nutraceutical industry.
Market Position and Competitive Differentiation
Chromadex distinguishes itself by focusing on the intersection of scientific innovation and consumer wellness. Its emphasis on NAD+ research, an area that has increasingly become synonymous with the study of aging and cellular health, sets it apart in a competitive landscape that includes various bioscience and nutraceutical companies. The company’s multidimensional approach, which bridges direct consumer engagement with deep scientific inquiry, provides a unique value proposition that caters both to health-conscious individuals and to industry partners seeking high-quality, science-backed ingredients.
Commitment to Transparency and Quality
Transparency in research and product development is a core tenet of Chromadex’s philosophy. Every stage of its process—from initial scientific exploration to the final formulation—undergoes rigorous analytical review and quality control. This disciplined approach reassures consumers and industry collaborators alike, fostering trust and establishing Chromadex as a reliable source of scientifically supported nutraceutical innovations.
Integrating Science and Consumer Wellness
The company’s approach is marked by a detailed understanding of biochemical processes and a commitment to translating this expertise into practical health solutions. With its diversified business segments, Chromadex not only addresses the needs of a broad consumer base but also solidifies its reputation among researchers and industry experts. Its dedicated exploration of key ingredients such as nicotinamide riboside, alongside other innovative compounds, continues to influence the realm of healthy aging and functional nutrition.
ChromaDex Corp. (CDXC) reported record revenue of $21.0 million for Q4 2022, an 18% increase year-over-year. Tru Niagen® sales rose by 14% to $16.1 million. Despite a net loss of $1.4 million, adjusted EBITDA improved to a profit of $0.4 million, reflecting operational efficiency. Full year sales totaled $72.0 million, up 7%, driven by e-commerce growth. The company signed a long-term agreement with Nestlé Health Science and received two new U.S. patents. Looking ahead, ChromaDex expects at least 10% revenue growth in 2023 amidst economic uncertainty, while projecting stable gross margins and reduced administrative expenses.
ChromaDex Corp. (NASDAQ:CDXC) announced its participation at the 35th Annual ROTH Capital Partners Conference in Dana Point, CA. CEO Rob Fried will present in a fireside chat on March 13th at 11:00 a.m. PT, highlighting ChromaDex's dedication to healthy aging and its pioneering research on NAD+.
The event, one of the largest for small-cap companies, includes presentations, Q&A sessions, and one-on-one meetings with investors. ChromaDex has been recognized as a distinguished healthcare sector presenter.
For more details, visit www.chromadex.com.
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on March 8, 2023, at 4:30 p.m. ET to discuss its fourth quarter and fiscal year 2022 financial results, with results released post-market. Participants are encouraged to dial in 10 minutes prior. The call will be available for replay from 7:30 p.m. ET on March 8 to 11:59 p.m. ET on March 14. ChromaDex specializes in bioscience focused on healthy aging and is known for its innovative NAD+ precursor, Niagen®. The company emphasizes research on nicotinamide adenine dinucleotide (NAD+) and its effects on aging.
ChromaDex Corp. (NASDAQ: CDXC) has expanded its patent portfolio for dihydronicotinamide riboside (NRH) with U.S. Patent 11,584,770, securing composition claims for purities over 90% chemical and 98% beta. This patent bolsters ChromaDex's leadership in the NAD+ precursor sector, allowing for future innovations in health supplements and pharmaceuticals. Preclinical studies suggest NRH is a potent NAD+ precursor, potentially outperforming existing options. The patent offers protection until 2034, enhancing the commercial viability of NRH and related products.
ChromaDex (NASDAQ: CDXC) provided an update on its intellectual property following a U.S. Court of Appeals decision affirming the invalidity of the 807 Dartmouth patent. The company asserts this judgment will not materially impact its nicotinamide riboside (NR) business, as it holds new patents obtained last year, ensuring protection for NR for at least the next 10 years. The patents cover methods of making NR and its various salt forms. ChromaDex emphasizes the strength of its brand, Tru Niagen®, backed by rigorous scientific studies. Looking ahead, the company plans to announce innovations in the coming months.
ChromaDex Corp. (NASDAQ:CDXC) announced positive results from its first-ever human clinical trial on combined metabolic activator (CMA) supplementation for Alzheimer's disease (AD) patients. The study, detailed in the peer-reviewed journal Translational Neurodegeneration, involved 60 patients and showed a 29% improvement in cognitive function compared to only 14% in the placebo group after 84 days. CMA, which includes the proprietary niagen® ingredient alongside L-carnitine and others, also enhanced liver and kidney health markers. ChromaDex plans to initiate a Phase 3 study for further research into CMA as a therapeutic option for AD.
ChromaDex Corp. (NASDAQ:CDXC) announced results from a pioneering five-month clinical study on its proprietary ingredient, Niagen® (nicotinamide riboside or NR). The study, involving 20 identical twin pairs, demonstrated that NR supplementation significantly improved muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota composition. Results were published in Science Advances, marking a milestone as the longest NR supplementation study to date. NR increased mitochondrial DNA by ~30% and showed well-tolerance. However, the study had limitations, including a lack of parallel placebo arm for BMI-discordant twins, prompting further investigations.
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
What is Chromadex Corp's primary focus?
How does Chromadex generate its revenue?
What makes Chromadex's research unique?
What is the significance of nicotinamide riboside (NR) for Chromadex?
In which segments does Chromadex operate?
How does Chromadex ensure the quality and safety of its products?
How is Chromadex positioned within the competitive landscape?
What are the key benefits of Chromadex's integrated business model?
